Market Overview

Mindray Offers Statement on Masimo Suit, Says Will 'Vigorously Defend the Actions'

Related MR
Benzinga's Top Downgrades
UPDATE: Morgan Stanley Downgrades Mindray Medical International As Uncertainties Linger
Related MASI
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin Demonstrated Similar Precision As Hemoglobin From Point Of Care Devices
Retrospective Study Of Enhanced Recovery After Surgery Program For Patients Undergoing Colorectal Surgery, Which Included Fluid Therapy Tailored to Masimo's PVI, Showed Reduced Length Of Stay and Cost Savings

Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced a statement on Masimo Corporation's (NASDAQ: MASI) lawsuit against Mindray.

On December 21, 2012, Masimo Corporation ("Masimo") brought an action in the United States District Court for the Central District of California against Mindray DS USA Inc. and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Masimo alleges that Mindray DS USA, Inc.'s U.S. Beneview pulse oximeters and sensors infringe its nine asserted patents relating to pulse oximeters and sensors, and that Shenzhen Mindray Bio-Medical Electronics Co., Ltd breached its Purchase and License Agreement dated November 13, 2002, as amended, by failing to use best efforts to promote adoption of Masimo's oximeter technology. In addition to monetary damages, Masimo is seeking injunctive relief preventing further sale of Beneview products incorporating Mindray oximetry boards in the United States.

Mindray intends to vigorously defend the actions.

Posted-In: News Legal

 

Related Articles (MASI + MR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional